The Pfizer and Johnson & Johnson-backed cancer treatment developer is eyeing expansion in Asia after receiving $40m in additional series D funding.

An unnamed care provider has added $20m to the $80m the software-based therapeutics developer received from investors including Novartis and SoftBank in December.

Access Biotechnology and returning investor Eli Lilly were among the participants in a series B round for the RNA-based drug developer.

Susquehanna International Group looks set to exit the microbiome therapeutics developer, which has filed to raise up to $100m in its initial public offering.

Pfizer Ventures could be in line for an exit after AbbVie purchased a buyout option for Parkinson's disease drug developer Mitokinin.

Acorn Bioventures has led a series B round for the cancer-focused biopharmaceutical spinout of CU Boulder.

AbbVie has bought an exclusive option to acquire Mitokinin once the UCSF spinout completes IND-enabling studies for its Parkinson’s treatment.

Nationwide Ventures co-led a $15m series B round for the health data platform developer that included Aflac Corporate Ventures and Epsilon Health Investors.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

LabCorp Venture Fund, Bristol Myers Squibb and Takeda Ventures contributed to $7m in equity funding and a $6m convertible note for the cancer drug developer.